Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
Chronic Myeloid Leukemia|CML|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Ph+ ALL
Prescribed dose of Iclusig® in routine practice in Belgium, Prescribed dose of Iclusig® in milligrams., Up to 3 years
Overall clinical benefit rate of Iclusig® based on response criteria for CML or Ph+ ALL in Belgium, Includes treatment effectiveness, complete hematologic response, cytogenetic response, major molecular response., Up to 3 years|Estimate of additional health care utilization cost, Costs associated with the treatment of Iclusig®-related adverse events reported during the registry., Up to 3 years
This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.